These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20571535)

  • 1. Pharmacotherapy: Valvulopathy in patients treated for hyperprolactinemia?
    Droogmans S; Van Camp G
    Nat Rev Endocrinol; 2010 Jul; 6(7):357-8. PubMed ID: 20571535
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT
    Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
    Valassi E; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists].
    Gabalec F; Čáp J; Radocha J
    Vnitr Lek; 2017; 63(9):561-565. PubMed ID: 29120651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia.
    Stiles CE; Steeds RP; Drake WM
    Ann Endocrinol (Paris); 2021 Jun; 82(3-4):182-186. PubMed ID: 32178837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiopulmonary complications of ergot-derivative dopamine agonists.
    Rack MJ; Baran AS; Richert AC; Roffwarg HP
    J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
    [No Abstract]   [Full Text] [Related]  

  • 7. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
    Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
    Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonists and hyperprolactinaemia.
    Martin NM; Tan T; Meeran K
    BMJ; 2009 Mar; 338():b381. PubMed ID: 19258356
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine agonists and valvular heart disease.
    Stephens JW; Price DE; Ionescu A
    N Engl J Med; 2007 Apr; 356(16):1676; author reply 1678-80. PubMed ID: 17442913
    [No Abstract]   [Full Text] [Related]  

  • 10. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.
    Bogazzi F; Manetti L; Raffaelli V; Lombardi M; Rossi G; Martino E
    J Endocrinol Invest; 2008 Dec; 31(12):1119-23. PubMed ID: 19246980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.
    Sherlock M; Toogood AA; Steeds R
    Heart; 2009 Apr; 95(7):522-3. PubMed ID: 19174419
    [No Abstract]   [Full Text] [Related]  

  • 12. AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.
    Samson SL; Ezzat S
    Endocr Pract; 2014 Jun; 20(6):608-16. PubMed ID: 24969114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
    Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
    Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.
    Budayr A; Tan TC; Lo JC; Zaroff JG; Tabada GH; Yang J; Go AS
    BMC Endocr Disord; 2020 Feb; 20(1):25. PubMed ID: 32075620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine.
    Clausen MF; Rørth R; Torp-Pedersen C; Westergaard LM; Weeke PE; Gislason G; Køber L; Fosbøl E; Kristensen SL
    BMC Cardiovasc Disord; 2021 Dec; 21(1):622. PubMed ID: 34963443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
    Drake WM; Stiles CE; Bevan JS; Karavitaki N; Trainer PJ; Rees DA; Richardson TI; Baldeweg SE; Stojanovic N; Murray RD; Toogood AA; Martin NM; Vaidya B; Han TS; Steeds RP; ; Baldeweg FC; Sheikh UE; Kyriakakis N; Parasuraman SK; Taylor L; Butt N; Anyiam S
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4189-4194. PubMed ID: 27571182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.
    Steeds R; Stiles C; Sharma V; Chambers J; Lloyd G; Drake W
    Clin Endocrinol (Oxf); 2019 May; 90(5):662-669. PubMed ID: 30818417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cabergoline in hyperprolactinemia and valvular heart disease].
    Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
    Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach.
    Mann WA
    Eur J Clin Invest; 2011 Mar; 41(3):334-42. PubMed ID: 20955213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiac valvulopathy and dopamine agonist].
    Grandas F
    Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.